WO1988000944A1 - Thiazole derivatives - Google Patents
Thiazole derivatives Download PDFInfo
- Publication number
- WO1988000944A1 WO1988000944A1 PCT/JP1987/000166 JP8700166W WO8800944A1 WO 1988000944 A1 WO1988000944 A1 WO 1988000944A1 JP 8700166 W JP8700166 W JP 8700166W WO 8800944 A1 WO8800944 A1 WO 8800944A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl group
- general formula
- alkyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/58—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M105/00—Lubricating compositions characterised by the base-material being a non-macromolecular organic compound
- C10M105/08—Lubricating compositions characterised by the base-material being a non-macromolecular organic compound containing oxygen
- C10M105/32—Esters
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M111/00—Lubrication compositions characterised by the base-material being a mixture of two or more compounds covered by more than one of the main groups C10M101/00 - C10M109/00, each of these compounds being essential
- C10M111/04—Lubrication compositions characterised by the base-material being a mixture of two or more compounds covered by more than one of the main groups C10M101/00 - C10M109/00, each of these compounds being essential at least one of them being a macromolecular organic compound
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M169/00—Lubricating compositions characterised by containing as components a mixture of at least two types of ingredient selected from base-materials, thickeners or additives, covered by the preceding groups, each of these compounds being essential
- C10M169/04—Mixtures of base-materials and additives
Definitions
- R 3 represents a hydrogen atom or ⁇ Cs
- Lubazol group carboxyl group, carboxy-Ci ⁇
- R 14 is shows the hydrogen atoms' child, -C S alkyl group, full Eniru group or inhibit Dorokishi Ci ⁇ Gs alkyl group.
- the compound of the present invention obtained by the reaction shown in each of the above reaction schemes can be easily isolated and purified by a separation means for chemicals.
- the separating means include a solvent oil removal method, a recrystallization method, and column chromatography.
- carriers such as lactose, Excipients such as sucrose, sodium chloride, pudose, urea, starch, carbonated calcium carbonate, kaolin, microcrystalline cellulose, caicic acid, etc., water, ethanol, propanol, simple syrup, sucrose solution, starch Liquid, gelatin solution, ruboxime Potassium Le cellulose, shellac, methylation cellulose,-phosphate, binding agents such as poly Binirupirori de down, dry starch, alginic acid Na Bok Liu ⁇ , agar powder, laminaran powder, sodium hydrogen carbonate Na Bokuri um, carbonate Disintegrators such as 2 ⁇ calcium, poly-xylethylene sorbitan fatty acid ester, sodium lauryl sulfate, monoglyceride stearate, starch, lactose, sucrose, stealine, cocoa butter, hydrogenated Disintegration inhibitors, quaternary ammonium bases, absorption enhancers such as sodium lau
- compositions may include i *, Neissen's pharmaceuticals.
- the amount of the compound of the present invention to be contained in the pharmaceutical preparation of the present invention is not particularly limited and may be appropriately selected over a wide range, but is usually preferably from 7 to 70% by weight in the pharmaceutical preparation. ⁇
- Table 3 shows the physical properties.
- Table 4 shows the properties of these compounds.
- the number of viable cells was determined by staining dead cells with Tripan blue and subtracting them, and counting them using a hemocytometer.
- the cell concentration was prepared at 3 X 1 ⁇ 3 cells Z Ueru such that ⁇ 0? / 0 FBS pressurized DME. Thus, a cell suspension was prepared.
- the concentration of the test substance is serially doubled from 10 gzmfi.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8807032A GB2203146B (en) | 1986-08-04 | 1987-03-17 | Thiazole derivatives |
JP62501805A JPH0662413B1 (ja) | 1986-08-04 | 1987-03-17 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61/183873 | 1986-08-04 | ||
JP61183873A JPS6339868A (ja) | 1986-08-04 | 1986-08-04 | ジ低級アルキルフエノ−ル誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1988000944A1 true WO1988000944A1 (en) | 1988-02-11 |
Family
ID=16143319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1987/000166 WO1988000944A1 (en) | 1986-08-04 | 1987-03-17 | Thiazole derivatives |
Country Status (7)
Country | Link |
---|---|
US (1) | US5104889A (ja) |
EP (1) | EP0275312A4 (ja) |
JP (2) | JPS6339868A (ja) |
CH (1) | CH669790A5 (ja) |
DE (1) | DE3790438T1 (ja) |
GB (1) | GB2203146B (ja) |
WO (1) | WO1988000944A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071865A (en) * | 1989-06-14 | 1991-12-10 | Bayer Aktiengesellschaft | Pesticidal 2-acylamino-4-halogeno-5-nitrothiazoles |
JP2009513566A (ja) * | 2005-09-13 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 2−アニリン−4−アリール置換チアゾール誘導体 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990011278A1 (en) * | 1989-03-24 | 1990-10-04 | The Green Cross Corporation | Thiazole compounds and applications thereof |
US5102897A (en) * | 1990-03-27 | 1992-04-07 | Warner-Lambert Company | 3,5-ditertiarybutyl-4-hydroxyphenyl, 1,3,4-thiadiazoles and oxadiazoles linked by carbon, oxygen, and sulfur residues |
AU665184B2 (en) * | 1991-01-23 | 1995-12-21 | Gensia, Inc. | Adenosine kinase inhibitors |
WO1997047299A1 (en) * | 1996-06-12 | 1997-12-18 | 3-Dimensional Pharmaceuticals, Inc. | Amidino and guanidino heterocyclic protease inhibitors |
DE19700795A1 (de) * | 1997-01-13 | 1998-07-16 | Bayer Ag | Verwendung von Aminothiazolen zur Wund- und Hautbehandlung |
PL193438B1 (pl) * | 1997-06-24 | 2007-02-28 | Janssen Pharmaceutica Nv | Pochodna 5-podstawionego-1,2,4-tiadiazolilu, jej zastosowanie i sposób wytwarzania, kompozycja farmaceutyczna, karbotioaminowa pochodna piperazyny i sposób jej wytwarzania |
KR100523755B1 (ko) | 1997-06-24 | 2005-10-26 | 얀센 파마슈티카 엔.브이. | 혈관형성을 저해하는 티아디아졸릴 피리다진 유도체 |
US6833369B2 (en) | 1997-06-24 | 2004-12-21 | Janssen Pharmaceutica, Nv | Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivatives |
HU225154B1 (en) * | 1997-06-24 | 2006-07-28 | Janssen Pharmaceutica Nv | Angiogenesis inhibiting thiadiazolyl-pyridazine derivatives, process for producing them and pharmaceutical compositions containing the same |
US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
JP2002520324A (ja) * | 1998-07-10 | 2002-07-09 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成インヒビター |
US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
ES2391550T3 (es) * | 1999-04-15 | 2012-11-27 | Bristol-Myers Squibb Company | Inhibidores cíclicos de la proteína tirosina quinasa |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
US7208503B2 (en) * | 2000-04-21 | 2007-04-24 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives |
JP3836019B2 (ja) * | 2001-11-21 | 2006-10-18 | 松下電器産業株式会社 | 受信装置、送信装置及び送信方法 |
AP2358A (en) * | 2005-05-09 | 2012-01-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use. |
ATE466003T1 (de) * | 2005-08-05 | 2010-05-15 | Bristol Myers Squibb Co | Herstellung von 2-aminothiazol-5- carbonsäurederivaten |
AU2008313776B2 (en) | 2007-10-18 | 2013-12-05 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4-triazoles |
JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
CA2714662C (en) | 2008-03-19 | 2016-05-10 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators |
CL2009001125A1 (es) | 2008-05-09 | 2011-02-11 | Janssen Pharmaceutica Nv | Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. |
EP2388253B1 (en) | 2009-03-10 | 2015-02-11 | Gifu University | Thiazole derivative and process for producing same |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
JP7409696B2 (ja) | 2018-06-15 | 2024-01-09 | ハンダ ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤の塩およびその組成物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS395907B1 (ja) * | 1961-05-12 | 1964-04-30 | ||
JPS56120675A (en) * | 1980-01-29 | 1981-09-22 | Hoechst Ag | Novel carboxylic acid derivative |
JPS57175171A (en) * | 1981-04-21 | 1982-10-28 | Yamanouchi Pharmaceut Co Ltd | 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compound |
JPS57183767A (en) * | 1981-03-18 | 1982-11-12 | Ciba Geigy Ag | Novel thiazole derivative, manufacture, pharmacological medicine containing same and use as medicine |
JPS5857366A (ja) * | 1981-10-02 | 1983-04-05 | Yamanouchi Pharmaceut Co Ltd | 3,5−ジ−tert−ブチル−4−ヒドロキシフエニル置換複素環化合物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL264710A (ja) * | 1960-05-13 | |||
US3201409A (en) * | 1961-04-24 | 1965-08-17 | John D Spivack | 2-substituted aminothiazoles |
US3299087A (en) * | 1961-04-24 | 1967-01-17 | Geigy Chem Corp | Nu, nu'-bis-(thiazolyl)-phenylenediamines |
US3467666A (en) * | 1966-11-07 | 1969-09-16 | Geigy Chem Corp | 2-substituted aminothiazoles |
JPS5537555B2 (ja) * | 1973-10-24 | 1980-09-29 | ||
JPS565747B2 (ja) * | 1973-10-24 | 1981-02-06 | ||
JPS5537556B2 (ja) * | 1973-12-27 | 1980-09-29 | ||
JPS5742629B2 (ja) * | 1973-10-29 | 1982-09-09 | ||
JPS5175065A (ja) * | 1974-12-06 | 1976-06-29 | Shionogi Seiyaku Kk | |
JPS5833870B2 (ja) * | 1976-01-12 | 1983-07-22 | 塩野義製薬株式会社 | チアゾリン誘導体 |
US4636516A (en) * | 1981-02-19 | 1987-01-13 | Yamanouchi Pharmaceutical Co., Ltd. | 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds |
FR2581063B1 (fr) * | 1985-04-30 | 1987-07-17 | Chauvin Blache Lab | Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique |
JPS6287580A (ja) * | 1985-10-14 | 1987-04-22 | Otsuka Pharmaceut Factory Inc | p−アミノフエノ−ル誘導体 |
JPS62123180A (ja) * | 1985-11-21 | 1987-06-04 | Otsuka Pharmaceut Factory Inc | p−アミノフエノ−ル誘導体 |
-
1986
- 1986-08-04 JP JP61183873A patent/JPS6339868A/ja active Pending
-
1987
- 1987-03-17 EP EP19870901688 patent/EP0275312A4/en not_active Withdrawn
- 1987-03-17 DE DE19873790438 patent/DE3790438T1/de not_active Withdrawn
- 1987-03-17 JP JP62501805A patent/JPH0662413B1/ja not_active Withdrawn
- 1987-03-17 WO PCT/JP1987/000166 patent/WO1988000944A1/ja not_active Application Discontinuation
- 1987-03-17 GB GB8807032A patent/GB2203146B/en not_active Expired - Fee Related
-
1988
- 1988-03-17 CH CH1269/88A patent/CH669790A5/de not_active IP Right Cessation
-
1990
- 1990-05-29 US US07/529,694 patent/US5104889A/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS395907B1 (ja) * | 1961-05-12 | 1964-04-30 | ||
JPS56120675A (en) * | 1980-01-29 | 1981-09-22 | Hoechst Ag | Novel carboxylic acid derivative |
JPS57183767A (en) * | 1981-03-18 | 1982-11-12 | Ciba Geigy Ag | Novel thiazole derivative, manufacture, pharmacological medicine containing same and use as medicine |
JPS57175171A (en) * | 1981-04-21 | 1982-10-28 | Yamanouchi Pharmaceut Co Ltd | 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compound |
JPS5857366A (ja) * | 1981-10-02 | 1983-04-05 | Yamanouchi Pharmaceut Co Ltd | 3,5−ジ−tert−ブチル−4−ヒドロキシフエニル置換複素環化合物 |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 81, No. 15, Abstract No. 81:91407z, 1974 (Columbus, Ohio, U.S.A.) DESHPANDE, R. N., et. al., J. Prakt. Chem., 316(2), 349 * |
See also references of EP0275312A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071865A (en) * | 1989-06-14 | 1991-12-10 | Bayer Aktiengesellschaft | Pesticidal 2-acylamino-4-halogeno-5-nitrothiazoles |
JP2009513566A (ja) * | 2005-09-13 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 2−アニリン−4−アリール置換チアゾール誘導体 |
Also Published As
Publication number | Publication date |
---|---|
US5104889A (en) | 1992-04-14 |
EP0275312A4 (en) | 1988-11-14 |
DE3790438T1 (ja) | 1988-08-25 |
GB8807032D0 (en) | 1988-05-25 |
CH669790A5 (ja) | 1989-04-14 |
JPH0662413B1 (ja) | 1994-08-17 |
EP0275312A1 (en) | 1988-07-27 |
JPS6339868A (ja) | 1988-02-20 |
GB2203146B (en) | 1991-01-23 |
GB2203146A (en) | 1988-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1988000944A1 (en) | Thiazole derivatives | |
CN113194958B (zh) | THRβ受体激动剂化合物及其制备方法和用途 | |
EP2484669B1 (en) | Phenol derivatives | |
US6608101B1 (en) | 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | |
FI91869C (fi) | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi | |
JP2703408B2 (ja) | 1,4‐ベンゾチアゼピン誘導体 | |
US20040248950A1 (en) | Apo ai expression accelerating agent | |
AU2004259000A1 (en) | Design and synthesis of optimized ligands for PPAR | |
EP3828183A1 (en) | Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | |
EP2907805A1 (en) | Novel pyrazole derivative | |
EP2496230B1 (en) | Ire-1 alpha inhibitors | |
KR20210079290A (ko) | 비알코올성 지방 간 질환의 치료 | |
CN102428073B (zh) | 咪唑烷-2,4-二酮衍生物及其作为癌症药物的用途 | |
AU2012345843A1 (en) | Improved modulators of Hec1 activity and methods therefor | |
WO2005035512A1 (ja) | チアジアゾリン誘導体 | |
US11584722B2 (en) | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | |
WO2002076177A2 (en) | Design and synthesis of optimized ligands for ppar | |
KR20080003924A (ko) | 염기성 질소를 갖지 않는 신규 티아졸리디논, 그의 제법,및 약제로서의 그의 용도 | |
JPH0692360B2 (ja) | 新規のベンゾセレナゾリノン化合物、これらを調製するプロセスおよびそれらを含む薬剤組成物 | |
KR20080005971A (ko) | 염기성 질소를 갖지 않는 신규 티아졸리디논, 그의 제법,및 약제로서의 그의 용도 | |
US20030171390A1 (en) | Modulators of Rho C activity | |
JP2602735B2 (ja) | 抗活性酸素剤 | |
WO2000029375A1 (fr) | Composes bysaryle et medicaments contre le cancer contenant lesdits composes | |
EP0080419B1 (fr) | Haloalkyl-8-4H-(1)-benzopyran-4-ones, et procédés de préparation | |
FR2693196A1 (fr) | Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CH DE GB JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): FR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1987901688 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1987901688 Country of ref document: EP |
|
RET | De translation (de og part 6b) |
Ref document number: 3790438 Country of ref document: DE Date of ref document: 19880825 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3790438 Country of ref document: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1987901688 Country of ref document: EP |